70705-30-5

Usage

Uses

Used in Organic Chemistry Research:
Ethyl 6-methylimidazo[1,2-a]pyridine-2-carboxylate is used as a research chemical for studying the properties and reactions of imidazo[1,2-a]pyridines. Its unique molecular structure allows for exploration of its potential applications in various chemical processes and synthesis.
Used in Pharmaceutical Development:
In the pharmaceutical industry, Ethyl 6-methylimidazo[1,2-a]pyridine-2-carboxylate is used as a starting material or intermediate in the synthesis of potential drug candidates. Its imidazo[1,2-a]pyridine moiety may offer therapeutic benefits in the development of new medications.
Used in Chemical Synthesis:
Ethyl 6-methylimidazo[1,2-a]pyridine-2-carboxylate is utilized as a synthetic building block in the preparation of more complex organic molecules. Its reactivity and functional groups make it a valuable component in the synthesis of various organic compounds.
Safety Precautions:
Due to its nature as a laboratory chemical, Ethyl 6-methylimidazo[1,2-a]pyridine-2-carboxylate should be handled with care to prevent potential health hazards or adverse reactions. Proper safety measures, such as wearing protective gear and working in a well-ventilated area, should be followed during its use.

InChI:InChI=1/C11H12N2O2/c1-3-15-11(14)9-7-13-6-8(2)4-5-10(13)12-9/h4-7H,3H2,1-2H3

Upstream product

• 72721-17-6 ethyl 6-methyl-3,5-dinitroimidazo<1,2-a>pyridine-2-carboxylate 
• 1603-41-4 (5-methyl-pyridin-2-yl)amine 
• 70-23-5 ethyl Bromopyruvate 

Downstream Products

• 859788-42-4 3-(2-ethoxy-benzoylamino)-6-methyl-imidazo[1,2-a]pyridine-2-carboxylic acid amide 
• 859788-68-4 3-(2-ethoxy-phenyl)-6-methyl-2H-2,4,4b,9-tetraaza-fluoren-1-one 
• 926223-25-8 (6-methylimidazo[1,2-a]pyridin-2-yl)methanol 

Relevant academic research and scientific papers

Microwave-Assisted Suzuki–Miyaura and Sonogashira Coupling of 4-Chloro-2-(trifluoromethyl)pyrido[1,2-e]purine Derivatives

The convenient preparation of three imidazo[1,2-a]pyridine-2-carboxamide intermediates is reported through known Strecker–Ugi type multicomponent reactions, Tschitschibabin type condensations, and further synthetic sequences. The derivatives were then efficiently converted to novel 4-chloro-2-(trifluoromethyl)pyrido[1,2-e]purines by their original reactions with 2,2,2-trifluoroacetamide, followed by subsequent dehydroxychlorination reactions. These compounds were cross-coupled under microwave irradiation through SuzukiMiyaura and Sonogashira palladium(0) catalysis to various aromatic and alkynyl reagents, thus providing the related C-4 substituted pyrido[1,2-e]purines of biological interest in good yields.

HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS

The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.

Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors

A series of imidazolepyridine derivatives were designed and synthesized according to the established docking studies. The imidazopyridine derivatives were found to have good potency and physical-chemical properties. Several highly potent compounds such as 8ji, 8jl, and 8jm were identified with single nanomolar activities. The most potent compound 8jm showed an IC50 of 3 nM, lower microsome clearance and no CYP inhibition. The profile of 8jm appeared to be superior to BMS433771, and supported further optimization.

COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY

Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy.

CHEMICAL COMPOUNDS 637

The present invention provides a compound of a formula (I), wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE4 mediated disease state.

Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives

Synthesis and primary SAR of a novel series of 2-phenylpyrido[1,2-e]purin- 4(3H)-one derivatives with piperazinyl sulfonamide substituents were described herein. As potential PDE5 inhibitors for erectile dysfunction (ED) treatment, representative compound

Chemical compounds

The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.

peri-Substituted Imidazopyridines. A New Reductive Elimination Reaction

A new reductive elimination reaction of 3,5-disubstituted imidazopyridines (3) with hydrazine is reported.Thus on treatment of the 3,5-dibromo (7a), 5-bromo-3-nitro (7b), and 3,5-dinitro (4) derivatives with hydrazine hydrate in hot ethanol, the bromine and nitro groups are replaced by hydrogen.A mechanism based on the conjugated relationship of these peri-substituents is proposed and used to explain the reported conversion of 1,3,5-trichloro-2,4,6-trinitrobenzene (9) into 1,3-dichloro-4,6-dinitrobenzene (10).A variety of other 3-nitro-5-substituted imidazopyridines (15)-(18) is described, but these could not be cyclised to 1,2,4-triazacyclopentindenes.The 3-amino-5-methoxycarbonyl derivative (19a) cyclises to the triazacyclopentindenone (20) with sodium methoxide.